ASCO Genitourinary Cancers Symposium


 

ASCO GU 2022 TROPHY-U-01 Cohort 3: Sacituzumab Govitecan + Pembrolizumab in mUC After Progression With Platinum-Based Regimens

108 views
March 8, 2022
0 Comments
Login to view comments. Click here to Login